What examinations and monitoring items need to be done before taking momelotinib?

Before starting to take molotinib (Momelotinib), patients need to undergo a series of basic examinations and assessments to ensure the safety of the medication and provide a reference for subsequent course monitoring. First, hematology tests are performed, including a complete blood count, platelets, white blood cells, and red blood cell levels. These indicators can evaluate the patient's basic hematopoietic function. Especially for patients with myelofibrosis or other blood diseases, understanding platelet and hemoglobin levels is very critical for adjusting the initial dose and preventing severe myelosuppression.

Secondly, liver and kidney function tests are also essential. The metabolism of molotinib in the body mainly depends on the liver and is metabolized by the CYP3A enzyme system. At the same time, part of the drug is excreted by the kidneys. Therefore, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine, urea nitrogen and other indicators should be measured before medication. Patients with abnormal hepatic and renal function may need to adjust the starting dose or increase the frequency of follow-up to reduce the risk of drug-related toxicity.

In addition, an electrocardiogram (ECG) and cardiac evaluation are also important. Molotinib may have certain effects on cardiac electrophysiology, especially the risk of QT interval prolongation. An electrocardiogram before treatment can identify potential heart rhythm abnormalities, assess a patient's suitability for the drug, and provide baseline data for continuous monitoring during treatment. Some patients also need further cardiac function evaluation based on their past history of heart disease to prevent serious arrhythmias caused by drugs.

Finally, previous medication and comorbid diseases should also be evaluated to understand whether the patient is concurrently using strongCYP3A inhibitors or inducers, anticoagulants, or other hematological drugs. In addition, the patient's past bleeding history, infection history and other underlying diseases need to be assessed. This information has important reference value for formulating individualized treatment plans, predicting drug tolerance and setting monitoring frequency. Through comprehensive examination and evaluation, the foundation can be laid for safe and effective long-term treatment with molotinib while minimizing potential risks.

Reference materials:https://www.cancer.gov/about-cancer